APA (7th ed.) Citation

E, M., CB, H., P, H., M, K., H, M., K, K., . . . M, K. (2023). Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Science translational medicine, 15(696), eabm1262. https://doi.org/10.1126/scitranslmed.abm1262

Chicago Style (17th ed.) Citation

E, Moles, et al. "Delivery of PEGylated Liposomal Doxorubicin by Bispecific Antibodies Improves Treatment in Models of High-risk Childhood Leukemia." Science Translational Medicine 15, no. 696 (2023): eabm1262. https://doi.org/10.1126/scitranslmed.abm1262.

MLA (9th ed.) Citation

E, Moles, et al. "Delivery of PEGylated Liposomal Doxorubicin by Bispecific Antibodies Improves Treatment in Models of High-risk Childhood Leukemia." Science Translational Medicine, vol. 15, no. 696, 2023, p. eabm1262, https://doi.org/10.1126/scitranslmed.abm1262.